Growth hormone deficiency pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(16 intermediate revisions by 3 users not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{MAD}}
{{CMG}}; {{AE}} {{MAD}}


==Overview==
==Overview ==
The [[Somatotroph|somatotroph cells]] of the anterior pituitary gland produce growth hormone (GH). GH best-known effect is increasing body mass. GH causes [[epiphyseal plate]] widening and [[cartilage]] growth. GH deficiency results in alterations in the physiology of different systems of the body, manifesting as altered [[lipid]] metabolism, increased subcutaneous visceral fat, decreased [[muscle mass]]. Genetic basis of congenital growth hormone deficiency depends on many genes, for example, ''POU1F1'' gene mutations are the most common known genetic cause of the combined [[Pituitary gland|pituitary]] hormone deficiency. Gene deletions, f[[Frameshift mutation|rameshift]] mutations, and [[nonsense mutations]] of ''GH1 gene'' have been described as causes of familial GHD.
The [[Somatotrophs|somatotroph cells]] of the [[Anterior pituitary gland|anterior pituitary organ]] produce [[growth hormone]] ([[Growth hormone|GH]]). The most widely studied impact of growth hormone is increasing [[weight]]. [[Growth hormone|GH]] causes [[epiphyseal plate]] broadening and [[ligament]] development. [[Growth hormone|GH]] deficiency results in alterations in the [[physiology]] of different systems of the body, manifesting as altered [[lipid metabolism]], increased [[Subcutaneous tissue|subcutaneous]] [[visceral]] [[fat]], decreased [[muscle mass]], decreased [[bone density]], low exercise performance, and reduced quality of life. The hereditary premise of inborn growth hormone deficiency relies upon numerous factors; POU1F1 quality transformations are the most widely recognized hereditary reason for the joined [[pituitary hormone]] lack. Quality [[Deletion (genetics)|deletions]], [[Frameshift mutation|frameshift]] transformations, and jabber changes of GH1 quality have been described as reasons for familial GHD.


==Pathophysiology==
==Pathophysiology==
Line 10: Line 10:
* They are regulated by two [[Hypothalamus|hypothalamic]] hormones; [[GHRH|GH-releasing hormone]] ([[GHRH]]) stimulates and [[somatostatin]] inhibits them.  
* They are regulated by two [[Hypothalamus|hypothalamic]] hormones; [[GHRH|GH-releasing hormone]] ([[GHRH]]) stimulates and [[somatostatin]] inhibits them.  


* GH effect is increasing [[body mass]]:  
* GH increases [[body mass]] by:  
**GH increases total body [[protein]] content and is associated with an increase in [[amino acid]] incorporation into [[cartilage]] and [[bone]].<ref name="pmid13319878">{{cite journal| author=MURPHY WR, DAUGHADAY WH, HARTNETT C| title=The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat. | journal=J Lab Clin Med | year= 1956 | volume= 47 | issue= 5 | pages= 715-22 | pmid=13319878 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13319878  }}</ref>  
**Increasing total body [[protein]] content and is associated with an increase in [[amino acid]] incorporation into [[cartilage]] and [[bone]].<ref name="pmid13319878">{{cite journal| author=MURPHY WR, DAUGHADAY WH, HARTNETT C| title=The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat. | journal=J Lab Clin Med | year= 1956 | volume= 47 | issue= 5 | pages= 715-22 | pmid=13319878 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13319878  }}</ref>  
**GH stimulates l[[Lipolysis|ipolysis]] decreasing total body [[fat]] content.
**Stimulation of l[[Lipolysis|ipolysis]] decreasing total body [[fat]] content.
**GH also increases [[bone mass]] by stimulating skeletal [[insulin-like growth factor-I]] and causing [[hypertrophy]] of [[osteoblasts]], bone remodeling, and [[mineralization]]. GH decreases expression of adipocyte maturation regulators (''C/EBPα'', ''PPARγ'') and prominent genes related to lipid synthesis such as ''FAS'' and ''FABP.'' GH treatment increased the mRNA expression of ''adiponectin'' and ''UCP1'' in mature adipocytes.<ref name="pmid15689575">{{cite journal| author=Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M et al.| title=Endocrine control of body composition in infancy, childhood, and puberty. | journal=Endocr Rev | year= 2005 | volume= 26 | issue= 1 | pages= 114-46 | pmid=15689575 | doi=10.1210/er.2003-0038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15689575  }}</ref>
**Increasing [[bone mass]] by stimulating skeletal [[insulin-like growth factor-I]], causing [[hypertrophy]] of [[osteoblasts]], bone remodeling, and [[mineralization]].  
**GH causes [[epiphyseal plate]] widening and [[cartilage]] growth. 
**Decreasing the expression of [[adipocyte]] maturation regulators ([[CEBPA|''C/EBPα'',]] ''[[PPAR|PPARγ]]'') and prominent genes related to [[lipid]] synthesis such as ''[[FAS ligand|FAS]]'' and ''[[FABP1|FABP]].''  
**Increasing the [[Messenger RNA|mRNA]] expression of ''[[adiponectin]]'' and ''[[UCP1]]'' in mature [[adipocytes]] causing [[epiphyseal plate]] widening and [[cartilage]] growth.<ref name="pmid15689575">{{cite journal| author=Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M et al.| title=Endocrine control of body composition in infancy, childhood, and puberty. | journal=Endocr Rev | year= 2005 | volume= 26 | issue= 1 | pages= 114-46 | pmid=15689575 | doi=10.1210/er.2003-0038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15689575  }}</ref>


*[[Growth hormone|GH]] deficiency results in alterations in the physiology of different systems of the body, manifesting as altered [[lipid metabolism]], increased subcutaneous visceral [[fat]], decreased [[muscle mass]], decreased [[bone density]], low exercise performance, and reduced quality of life.
*[[Growth hormone|GH]] deficiency results in alterations in the [[physiology]] of different systems of the body, manifesting as altered [[lipid metabolism]], increased [[Subcutaneous tissue|subcutaneous]] [[visceral]] [[fat]], decreased [[muscle mass]], decreased [[bone density]], low exercise performance, and reduced quality of life.


== Regulation of growth hormone secretion ==
== Regulation of growth hormone secretion ==
* The secretion of growth hormone (GH) is controlled by a complex regulatory system. Primarily, it is controlled by two hormones; GH-releasing hormone and somatostatin.
* The secretion of [[growth hormone]] is controlled by a complex regulatory system. Primarily, it is controlled by two [[hormones]]; [[Growth hormone releasing hormone|GH-releasing hormone]] and [[somatostatin]].


* The adenylate cyclase-cyclic AMP-protein kinase A plays a major role in the control of GH secretion by GH-releasing hormone.
* The [[adenylate cyclase]]-[[cyclic AMP]]-[[protein kinase A]] plays a major role in the control of GH secretion by [[Growth hormone releasing hormone|GH-releasing hormone]].
* GH gene expression is also of importance in determining the GH responses.
* GH gene expression is also of importance in determining the [[Growth hormone|GH]] response.
* GH secretion is pulsatile; between pulses, serum GH concentration may be undetectable unless an ultrasensitive assay is employed. It is thought that the pulsatile bursts of GH release are mediated by the reduction in tonic inhibition by somatostatin, perhaps in association with bursts of GHRH [11,21].  
* GH secretion is [[Pulsatile flow|pulsatile]]; between pulses, serum GH concentration may be undetectable. It is thought that the pulses of GH release are mediated by the reduction in inhibition by [[somatostatin]] with an increase of [[GHRH]].
 
* The glucocorticoids play a principal role in the functional maturation of GH cells in the fetal pituitary glands in rodents, inducing GH and GHRH-receptor gene expression, and establish the GH secretory system.
* During human pubertal development, there is an augmentation of GH secretion with a subsequent return to or a fall below prepubertal values in early adulthood.(2)


* The [[glucocorticoids]] play a principal role in the functional maturation of [[Growth hormone|GH]] cells in the fetal [[Pituitary gland|pituitary glands]], inducing [[Growth hormone|GH]] and [[Growth hormone-releasing hormone|GHRH-receptor]] [[gene expression]], and development of the [[Growth hormone|GH]] secretory system.
* During [[puberty]], there is a temporary increase in [[Growth hormone|GH]] secretion with a subsequent return to the normal values in early adulthood.
[[File:1809 Hormonal Regulation of Growth.jpg|500px|center|thumb|Growth hormone secretion regulations, source: By OpenStax College - Anatomy & Physiology, Connexions Web site. httpcnx.orgcontentcol114961.6, Jun 19, 2013., CC BY 3.0, httpscommons.wikimedia.orgwindex.phpcurid=30148146]]
== Molecular effects of growth hormone on cells ==
== Molecular effects of growth hormone on cells ==
* GH stimulated cell proliferation in both trabecular and stromal osteoblasts.
* [[Growth hormone]] acts by binding to the [[Receptor (biochemistry)|receptor]] [[homodimer]] in the [[liver]].
* Human trabecular osteoblasts produce mainly IGF-II, IGFBP-3 and minute quantities of IGF-I in culture.
* The [[Receptor (biochemistry)|receptor]] consists of an [[extracellular]] [[Ligand (biochemistry)|ligand-binding]] [[Domain (biology)|domain]] and a [[Cytoplasm|cytoplasmic]] signaling part.
* IGFs and their binding proteins may exert important regulatory effects on the biological effects of GH on human osteoblasts.
* GH acts to stimulate hepatic synthesis and secretion of [[Insulin-like growth factor-I|insulin-like growth factor-1]] ([[Insulin-like growth factor-I|IGF-1]]).
 
* [[Insulin-like growth factor-I|IGF-1]] is a [[protein]] responsible for most of the growth-promoting activities of [[Growth hormone|GH]].  
* Growth hormone (GH) acts by binding to a specific receptor homodimer, located mostly in the liver.
* [[Insulin-like growth factor-I|IGF-1]] directly inhibits [[Growth hormone|GH]] secretion and GH [[Receptor (biochemistry)|receptor]] function by a negative feedback effect.
* The receptor consists of an extracellular ligand-binding domain, a single membrane-spanning domain, and a cytoplasmic signaling component.
* [[Growth hormone|GH]] stimulates [[cell proliferation]] in [[osteoblasts]]. Human [[Trabecular bone|trabecular]] [[osteoblasts]] produce mainly [[Insulin-like growth factor 2|IGF-II]], IGFBP-3 and fewer quantities of [[IGF-I]] in culture.  
* Its predominant action is to stimulate hepatic synthesis and secretion of insulin-like growth factor-1 (IGF-1), a potent growth and differentiation factor [1].
* IGFs and their binding [[proteins]] may exert important regulatory effects on the [[Growth hormone|GH]] effect on [[osteoblasts]].  
* IGF-1 is a critical protein induced by GH and is likely responsible for most of the growth-promoting activities of GH [33].  
[[File:Growth liver.png|300px|center|thumb| Growth hormone peripheral action, source: By Mikael Häggström.When using this image in external works, it may be cited asHäggström, Mikael (2014). Medical gallery of Mikael Häggström 2014. WikiJournal of Medicine 1 (2). DOI10.15347wjm2014.008. ISSN 2002-4436]]
* IGF-1 also directly inhibits GH secretion [33] and GH receptor function [34] by a negative feedback regulation loop.
* A single GH molecule complexes with two GH receptor molecules, followed by rapid internal rotation, and activation of JAK2 tyrosine kinase, leading to phosphorylation of several cytoplasmic signaling molecules determining cell proliferation and differentiated function.
* Activation of Jak2 leads to mitogenic proliferation, phosphorylation of intracellular proteins, MAP kinase activation, activation of Stats 1, 3, and 5, and induction of target gene expression.
* The STAT proteins comprise important signaling components for GH action.
* These cytoplasmic proteins are phosphorylated by JAK2 and directly translocated to the cell nucleus, where they elicit GH-specific target gene effects by binding to nuclear DNA. [1].
* STAT proteins 1 and 5 may also interact more directly with the GH receptor molecule [32]. STAT 5 plays important roles in the regulation of expression and in the sexually dimorphic expression of some liver genes.  
* a defect in GH-mediated JAK-STAT signal transduction could be a cause of the GH resistance that develops in the KD state and in this way contribute to the striking growth retardation that develops in this condition. In rats with chronic renal failure, a condition of acquired growth failure associated with GH resistance, we recently demonstrated that hepatic GH-dependent JAK-STAT signaling is impaired (22).  


==Genetic basis of growth hormone deficienc==
== Growth Hormone signaling ==
* A single [[Growth hormone|GH]] molecule binds with two GH [[Receptor (biochemistry)|receptor]] molecules, followed by activation of [[Janus kinase|JAK2 tyrosine kinase]] by [[phosphorylation]].
* [[Phosphorylation]] of [[JAK2]] leads to [[phosphorylation]] of intracellular proteins called [[STAT protein|STAT proteins]], [[MAP kinases|MAP kinase]] activation, and induction of [[gene expression]].
* These [[STAT protein|STAT proteins]] are [[phosphorylated]] by [[JAK2]] and directly translocated to the [[cell nucleus]], where they play the major control of [[Growth hormone|GH]]-specific [[gene]] effects by binding to [[nuclear DNA]].
* [[STAT5]] plays an important role in the regulation of expression of some [[Gene|genes]] in the [[liver]] [[Cell (biology)|cells.]]
* A defect in [[Growth hormone|GH]]-mediated [[JAK-STAT signaling pathway|JAK-STAT]] signal [[transduction]] could be a cause of the [[Growth hormone|GH]] resistance.
[[File:Growth Hormone-pathway-3.gif|350px|center|thumb|GH signaling]]


==Genetic basis of growth hormone deficiency==
==== ''[[POU1F1]]'' gene mutations ====
==== ''[[POU1F1]]'' gene mutations ====
* It is the most common known genetic cause of the combined [[Pituitary gland|pituitary]] hormone deficiency.<ref name="pmid26608600">{{cite journal| author=Ziemnicka K, Budny B, Drobnik K, Baszko-Błaszyk D, Stajgis M, Katulska K et al.| title=Two coexisting heterozygous frameshift mutations in PROP1 are responsible for a different phenotype of combined pituitary hormone deficiency. | journal=J Appl Genet | year= 2016 | volume= 57 | issue= 3 | pages= 373-81 | pmid=26608600 | doi=10.1007/s13353-015-0328-z | pmc=4963446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26608600  }}</ref>
* This is the most common known genetic cause of the combined [[Pituitary gland|pituitary]] hormone deficiency.<ref name="pmid26608600">{{cite journal| author=Ziemnicka K, Budny B, Drobnik K, Baszko-Błaszyk D, Stajgis M, Katulska K et al.| title=Two coexisting heterozygous frameshift mutations in PROP1 are responsible for a different phenotype of combined pituitary hormone deficiency. | journal=J Appl Genet | year= 2016 | volume= 57 | issue= 3 | pages= 373-81 | pmid=26608600 | doi=10.1007/s13353-015-0328-z | pmc=4963446 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26608600  }}</ref>
* It is responsible for [[Pituitary gland|pituitary]]-specific [[Transcription (genetics)|transcription]] of [[Gene|genes]] for GH, [[prolactin]], [[thyrotropin]], and the [[growth hormone releasing hormone|growth hormone-releasing hormone]] ([[GHRH]]) receptor.<ref name="pmid1977085">{{cite journal| author=Li S, Crenshaw EB, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG| title=Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. | journal=Nature | year= 1990 | volume= 347 | issue= 6293 | pages= 528-33 | pmid=1977085 | doi=10.1038/347528a0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1977085  }}</ref>
* It is responsible for [[Pituitary gland|pituitary]]-specific [[Transcription (genetics)|transcription]] of [[Gene|genes]] for GH, [[prolactin]], [[thyrotropin]], and the [[growth hormone releasing hormone|growth hormone-releasing hormone]] ([[GHRH]]) receptor.<ref name="pmid1977085">{{cite journal| author=Li S, Crenshaw EB, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG| title=Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. | journal=Nature | year= 1990 | volume= 347 | issue= 6293 | pages= 528-33 | pmid=1977085 | doi=10.1038/347528a0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1977085  }}</ref>
* ''PROP1'' [[mutations]] result in failure to activate ''POU1F1/Pit1'' [[gene expression]] and probably cause [[Pituitary gland|pituitary]] hypoplasia.<ref name="pmid9462743">{{cite journal| author=Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O'Connell SM et al.| title=Mutations in PROP1 cause familial combined pituitary hormone deficiency. | journal=Nat Genet | year= 1998 | volume= 18 | issue= 2 | pages= 147-9 | pmid=9462743 | doi=10.1038/ng0298-147 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9462743  }}</ref>
* ''PROP1'' [[mutations]] result in failure to activate ''POU1F1/Pit1'' [[gene expression]] and probably cause [[Pituitary gland|pituitary]] hypoplasia.<ref name="pmid9462743">{{cite journal| author=Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O'Connell SM et al.| title=Mutations in PROP1 cause familial combined pituitary hormone deficiency. | journal=Nat Genet | year= 1998 | volume= 18 | issue= 2 | pages= 147-9 | pmid=9462743 | doi=10.1038/ng0298-147 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9462743  }}</ref>


==== GH1 gene mutations ====
==== GH1 gene mutations ====
* It is ''GH1'' is the gene encoding GH, located on [[chromosome 17]].
* ''GH1'' gene encoding GH is located on [[chromosome 17]].
* [[Gene deletion|Gene deletions]], f[[Frameshift mutation|rameshift]] mutations, and [[nonsense mutations]] of ''GH1'' have been described as causes of familial GHD.
* [[Gene deletion|Gene deletions]], f[[Frameshift mutation|rameshift]] mutations, and [[nonsense mutations]] of ''GH1'' have been described as causes of familial GHD.


Line 68: Line 69:
==== '''Defective stabilization of circulating [[Insulin-like growth factor-I|IGF-I]]''' ====
==== '''Defective stabilization of circulating [[Insulin-like growth factor-I|IGF-I]]''' ====
* Acid-labile subunit is important for the stabilization of the [[Insulin-like growth factor-I|IGF-I]].
* Acid-labile subunit is important for the stabilization of the [[Insulin-like growth factor-I|IGF-I]].
* [[Mutations]] in the [[gene]] coding for it causes less stable and subsequently less effect.<ref name="pmid19729943">{{cite journal| author=Domené HM, Hwa V, Argente J, Wit JM, Wit JM, Camacho-Hübner C et al.| title=Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. | journal=Horm Res | year= 2009 | volume= 72 | issue= 3 | pages= 129-41 | pmid=19729943 | doi=10.1159/000232486 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19729943  }}</ref>
* [[Mutations]] in the [[gene]] coding for it causes less stable and subsequently less effective end product.<ref name="pmid19729943">{{cite journal| author=Domené HM, Hwa V, Argente J, Wit JM, Wit JM, Camacho-Hübner C et al.| title=Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. | journal=Horm Res | year= 2009 | volume= 72 | issue= 3 | pages= 129-41 | pmid=19729943 | doi=10.1159/000232486 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19729943  }}</ref>


==== '''[[Insulin-like growth factor-I|IGF-I]] receptor mutations''' ====
==== '''[[Insulin-like growth factor-I|IGF-I]] receptor mutations''' ====

Latest revision as of 16:15, 30 October 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency pathophysiology

CDC on Growth hormone deficiency pathophysiology

Growth hormone deficiency pathophysiology in the news

Blogs on Growth hormone deficiency pathophysiology

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

The somatotroph cells of the anterior pituitary organ produce growth hormone (GH). The most widely studied impact of growth hormone is increasing weight. GH causes epiphyseal plate broadening and ligament development. GH deficiency results in alterations in the physiology of different systems of the body, manifesting as altered lipid metabolism, increased subcutaneous visceral fat, decreased muscle mass, decreased bone density, low exercise performance, and reduced quality of life. The hereditary premise of inborn growth hormone deficiency relies upon numerous factors; POU1F1 quality transformations are the most widely recognized hereditary reason for the joined pituitary hormone lack. Quality deletions, frameshift transformations, and jabber changes of GH1 quality have been described as reasons for familial GHD.

Pathophysiology

Regulation of growth hormone secretion

Growth hormone secretion regulations, source: By OpenStax College - Anatomy & Physiology, Connexions Web site. httpcnx.orgcontentcol114961.6, Jun 19, 2013., CC BY 3.0, httpscommons.wikimedia.orgwindex.phpcurid=30148146

Molecular effects of growth hormone on cells

Growth hormone peripheral action, source: By Mikael Häggström.When using this image in external works, it may be cited asHäggström, Mikael (2014). Medical gallery of Mikael Häggström 2014. WikiJournal of Medicine 1 (2). DOI10.15347wjm2014.008. ISSN 2002-4436

Growth Hormone signaling

GH signaling

Genetic basis of growth hormone deficiency

POU1F1 gene mutations

GH1 gene mutations

Syndrome of bioinactive GH

GH receptor signal transduction

  • It is essential for normal signaling of the GH receptor. Mutations in the gene encoding signal transducer decrease the response of receptors to GH.[8]

IGF-I gene mutations

Defective stabilization of circulating IGF-I

  • Acid-labile subunit is important for the stabilization of the IGF-I.
  • Mutations in the gene coding for it causes less stable and subsequently less effective end product.[10]

IGF-I receptor mutations

References

  1. Cuttler L (1996). "The regulation of growth hormone secretion". Endocrinol Metab Clin North Am. 25 (3): 541–71. PMID 8879986.
  2. MURPHY WR, DAUGHADAY WH, HARTNETT C (1956). "The effect of hypophysectomy and growth hormone on the incorporation of labeled sulfate into tibial epiphyseal and nasal cartilage of the rat". J Lab Clin Med. 47 (5): 715–22. PMID 13319878.
  3. Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M; et al. (2005). "Endocrine control of body composition in infancy, childhood, and puberty". Endocr Rev. 26 (1): 114–46. doi:10.1210/er.2003-0038. PMID 15689575.
  4. Ziemnicka K, Budny B, Drobnik K, Baszko-Błaszyk D, Stajgis M, Katulska K; et al. (2016). "Two coexisting heterozygous frameshift mutations in PROP1 are responsible for a different phenotype of combined pituitary hormone deficiency". J Appl Genet. 57 (3): 373–81. doi:10.1007/s13353-015-0328-z. PMC 4963446. PMID 26608600.
  5. Li S, Crenshaw EB, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG (1990). "Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1". Nature. 347 (6293): 528–33. doi:10.1038/347528a0. PMID 1977085.
  6. Wu W, Cogan JD, Pfäffle RW, Dasen JS, Frisch H, O'Connell SM; et al. (1998). "Mutations in PROP1 cause familial combined pituitary hormone deficiency". Nat Genet. 18 (2): 147–9. doi:10.1038/ng0298-147. PMID 9462743.
  7. Besson A, Salemi S, Deladoëy J, Vuissoz JM, Eblé A, Bidlingmaier M; et al. (2005). "Short stature caused by a biologically inactive mutant growth hormone (GH-C53S)". J Clin Endocrinol Metab. 90 (5): 2493–9. doi:10.1210/jc.2004-1838. PMID 15713716.
  8. Hwa V, Camacho-Hübner C, Little BM, David A, Metherell LA, El-Khatib N; et al. (2007). "Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene". Horm Res. 68 (5): 218–24. doi:10.1159/000101334. PMID 17389811.
  9. Batey L, Moon JE, Yu Y, Wu B, Hirschhorn JN, Shen Y; et al. (2014). "A novel deletion of IGF1 in a patient with idiopathic short stature provides insight Into IGF1 haploinsufficiency". J Clin Endocrinol Metab. 99 (1): E153–9. doi:10.1210/jc.2013-3106. PMC 3879666. PMID 24243634.
  10. Domené HM, Hwa V, Argente J, Wit JM, Wit JM, Camacho-Hübner C; et al. (2009). "Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences". Horm Res. 72 (3): 129–41. doi:10.1159/000232486. PMID 19729943.
  11. Kawashima Y, Higaki K, Fukushima T, Hakuno F, Nagaishi J, Hanaki K; et al. (2012). "Novel missense mutation in the IGF-I receptor L2 domain results in intrauterine and postnatal growth retardation". Clin Endocrinol (Oxf). 77 (2): 246–54. doi:10.1111/j.1365-2265.2012.04357.x. PMID 22309212.